5 Key Takeaways

• 1

  Miguel Forte serves as President of ISCT, focusing on enhancing the society's global presence and establishing its clinical pillar.

• 2

  Patient access is currently the greatest challenge in cell and gene therapy, hindered by manufacturing capacity, clinical delivery, and reimbursement issues.

• 3

  Allogeneic cell therapies, especially those from induced pluripotent stem cells, are making significant progress but lack sufficient attention.

• 4

  Faster clinical trial approvals and pragmatic health technology assessments are essential for accelerating progress in cell and gene therapy.

• 5

  The integration of improved gene editing and AI is expected to transform drug development, making it more proactive and design-oriented.